A Phase 1/2 interventional study of LX2020 in Arrhythmogenic Cardiomyopathy, PKP2-ACM and PKP2-ARVC, sponsored by Lexeo Therapeutics. Active, not recruiting at 5 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-11-12.
Sponsored by Lexeo Therapeutics · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 231 studies in Cardiomyopathies with a site in United States — 56 open to participants now, 69 under way, 6 of them phase 3. Cardiomyopathies · United States.
Among the 231 studies in Cardiomyopathies with a site in United States, this one is the 109th largest by planned enrollment of the 132 interventional ones that give a count, is one of 12 that started in 2024, is one of 11 in phase 1/2, reaches primary completion later than 10 of the 67 other live ones, and was the 193rd registered.
556 studies on the registry are indexed under Cardiomyopathies; 153 are open to participants now.
Browse Cardiomyopathies studies →56 of the 231 studies in Cardiomyopathies with a site in United States are open now. Recruiting first, the newest first:
Atrium Therapeutics · Sites in United States
Ages 18–65
Eidos Therapeutics, a BridgeBio company · Sites in United States, Singapore, Spain
Ages 18–80
Vanderbilt University Medical Center · Sites in United States
Ages 8–18 · Men only
Old Dominion University · Sites in United States
Ages 18–85
Lexeo Therapeutics · Sites in United States, Brazil, Canada and 6 more countries
Ages 6+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 116 Cardiomyopathies studies recruiting now, 70 (60%) set no upper age limit and 18 (16%) stop at 75 or younger; 35 take children under 18; 22 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
231 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 29 · Phase 2 32 · Phase 3 20 · Phase 4 13
First in 1996; this study’s year is marked. 12 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 10 is below the median of 51 across 268 interventional studies indexed under Cardiomyopathies.
Median enrollment 42 across the 132 interventional studies, 160 across the 97 observational. Of the 139 that completed or were terminated, 65 (47%) have results posted.
This tab as a report to print or save as PDF → With an account.
73 of 231 have an industry lead sponsor. The 10 most frequent:
Lexeo Therapeutics is the lead sponsor of 8 studies on the registry; 4 are open to participants now.
Lexeo Therapeutics has 6 studies filed under Cardiomyopathies — fewer than ten, so there is no comparison to draw.
16 of the studies in Cardiomyopathies with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06109181Lexeo TherapeuticsGene Therapy for ACM Due to a PKP2 Pathogenic Variant | 2026-12 |
| NCT04520347University of California, Los AngelesIVTCC 2.0: A Prospective Multicenter Ventricular Tachycardia Catheter Ablation Registry | 2026-12 |
| NCT04843371Tulane UniversityPPG to Predict Ejection Fraction and Other Echographic Data in the General Population | 2026-12 |
| NCT03534726University of PennsylvaniaEdema and Fibrosis CMR Imaging in Cardiomyopathy | 2026-12-31 |
| NCT03049254Mayo ClinicMayo AVC Registry and Biobank | 2027-03 |
Add all 16 to your calendar (.ics) → With an account.
Among the 231 studies in Cardiomyopathies with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a Phase 1/2, first-in-human, open-label, intravenous, dose-escalating, multicenter trial that is designed to assess the safety and tolerability of LX2020 in adult patients with PKP2-ACM
Selected Inclusion Criteria:
Selected Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Single ascending dose of LX2020, with a starting dose of 2.0 x10\^13 gc/kg, in multiple cohorts
Genetic: LX2020
LX2020 is an adeno-associated viral vector encoding the human Plakophilin-2 (PKP2) gene (AAVrh.10hPKP2)
Percentage of subjects who experienced at least 1 treatment emergent adverse event (TEAE) and/or 1 treatment emergent serious adverse event (TESAE).
Evaluation of Safety and Tolerability of LX2020
Time frame: 12 months
Selected Exploratory
Change in the frequency of ventricular arrhythmias from baseline.
Time frame: 12 months
Started Feb 2024 (actual). Primary completion is estimated for Dec 2026, 34 months after the start.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Lexeo Therapeutics